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The Public Health Laboratory Service receives antibiotic susceptibility data for bacteria from bloodstream
infections from most hospitals in England and Wales. These data were used to ascertain resistance trends
to ciprofloxacin from 1990 through 1999 for the most prevalent gram-negative agents: Escherichia coli,
Klebsiella spp., Enterobacter spp., and Proteus  mirabilis. Significant increases in resistance were
observed for all four species groups. For E. coli, ciprofloxacin resistance rose from 0.8% in 1990 to 3.7% in
1999 and became widely scattered among reporting hospitals. The prevalence of resistance in Klebsiella
spp. rose from 3.5% in 1990, to 9.5% in 1996 and 7.1% in 1999, while that in Enterobacter spp. rose from
2.1% in 1990 to 10.5% in 1996 and 10.9% in 1999. For both Klebsiella and Enterobacter spp., most resis-
tance was localized in a few centers. Resistance was infrequent and scattered in P. mirabilis, but reached
a prevalence of 3.3% in 1999.
luoroquinolone antimicrobial drugs were a major thera-
peutic advance of the 1980s because they have 100-fold
greater activity than their parent compound, nalidixic acid (1).
Unlike nalidixic acid, which is used only for urinary infections
and occasionally shigellosis, the fluoroquinolones have a
broad range of therapeutic indications and are given as pro-
phylaxis, e.g., for neutropenic patients. In veterinary medicine
fluoroquinolones are used as treatment and metaphylaxis but
not as growth promoters. Early researchers thought that fluoro-
quinolone resistance was unlikely to evolve, largely because
resistant Escherichia coli mutants are exceptionally difficult to
select in vitro (2) and because plasmid-mediated quinolone
resistance remained unknown even after 30 years of nalidixic
acid usage. Nevertheless, mutational fluoroquinolone resis-
tance emerged readily in staphylococci and pseudomonads,
which are inherently less susceptible than E. coli. More
recently, fluoroquinolone resistance has emerged in E. coli and
other  Enterobacteriaceae, contingent on multiple mutations
that diminish the affinity of its topoisomerase II and IV targets
in various ways, reduce permeability, and upregulate efflux
(3). Plasmid-mediated quinolone resistance has been reported,
but it is exceptional (4). 
We report here resistance trends to ciprofloxacin, the most
widely used fluoroquinolone in the United Kingdom, in the
prevalent  Enterobacteriaceae species from bacteremias in
England and Wales during the 1990s.
Data Sources
Data Collection
The surveillance, described previously, depends on the
voluntary reporting of bloodstream isolates by hospital labora-
tories in England and Wales (5). The number of laboratories
reporting data has grown steadily: by 1998, 208 (91%) of the
229 establishments in England and Wales listed by the Associ-
ation of Medical Microbiologists were participating. Participa-
tion by laboratories in Scotland and Northern Ireland is
limited, and their data were excluded from our analysis. Most
laboratories used variants of Stokes’ disc method (6) for sus-
ceptibility tests in the period reviewed, but a minority used
breakpoint tests. Results reported as intermediate were
counted as resistant. Quality control was provided by the labo-
ratories’ participation in the National External Quality Assur-
ance Scheme and by comparison to results for the smaller
numbers of E. coli isolates from bloodstream infections tested
at the Central Public Health Laboratory (7). 
Prescribing Data for Fluoroquinolones
Prescribing data for fluoroquinolones, as defined daily
doses (8), were estimated for retail pharmacies by using IMS
HEALTH’s British Pharmaceutical Index (BPI) and for hospi-
tals by using Medicare Audit’s Hospital Pharmacy Audit
(HPA). The BPI records pharmaceutical sales to retail pharma-
cies and dispensing doctors in the United Kingdom, Channel
Islands, and the Isle of Man. Approximately 97% of whole-
saler sales to retail and physician outlets and >80% of direct
sales by manufacturers are recorded; other sales are estimated
from a sample of approximately 600 pharmacies. The number
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of pharmacies represented in the BPI remained constant during
the study period.
The HPA provides information on pharmaceutical con-
sumption by National Health Service hospitals, which account
for >95% of hospital care in the United Kingdom. Most hospi-
tals participate: approximately 93% of beds are currently cov-
ered. Since 1995, HPA data have been collected monthly from
the stock control systems of participating hospitals. Most data
are supplied electronically, which minimizes reporting errors.
Data include usage of pharmaceuticals among in- and outpa-
tient departments and for private patients in NHS hospitals but
not for private patients in designated private hospitals. Before
1995, HPA data were collected from wholesalers, manufactur-
ers, and a panel of hospitals: approximately 90% of indirect
sales to hospitals were received from wholesalers and approxi-
mately 40% of direct sales from manufacturers. The panel of
hospitals covered approximately 80% of beds in 1990 and
84.5% in 1995.
Statistical Analyses
Poisson regression was performed by using the log (total
number of isolates with resistance information) as an offset to
determine if the proportion of ciprofloxacin-resistant isolates
was changing with any type of pattern over time. S-Plus
(Mathsoft Inc., Seattle, WA) was used for calculation.
Results
Species Prevalence and Reporting Patterns
During the 1990s, the Public Health Laboratory Service
received nearly 392,551 reports of bacteremia in England and
Wales, including 132,311 that indicated E. coli, klebsiellae,
Enterobacter spp., and P. mirabilis as the pathogens isolated.
These four species groups thus accounted for 32% to 36% of
all bacteremia results in each year and for 71% to 72% of those
concerning gram-negative bacteria (Table 1). E. coli was the
most frequently reported pathogen, causing 22% to 25% of all
bacteremias in each year, whereas Klebsiella,  Proteus, and
Enterobacter spp. were among the 10 most frequent isolates.
The number of bacteremia reports rose each year (Table 1),
reflecting improved reporting rather than an increased inci-
dence of disease. A fall in the proportion of reports with sus-
ceptibility data in 1997 reflected early problems after a switch
to electronic reporting and was not exclusive to ciprofloxacin.
Resistance Trends for Ciprofloxacin 
Among the reports for E. coli, klebsiellae, Enterobacter
spp., and P. mirabilis, 75,168 (56.8%) had susceptibility data
for ciprofloxacin, confirming widespread testing. Ciprofloxa-
cin resistance was extremely rare when surveillance began but
subsequently increased for all four organisms (Figure 1). The
proportion of E. coli isolates reported as resistant rose slowly
but steadily, from 0.8% in 1990 to 3.7% in 1999. For Kleb-
siella spp., the resistance rate rose from 3.5% of reports in
1990 to 9.5% in 1996, before declining to 7.1% by 1999.
Enterobacter spp. showed a similar pattern to klebsiellae: the
prevalence of resistance rose from 2.1% in 1990 to 10.5% in
1996, then dipped to 7.9% in 1998 before rising to 10.9% in
1999. Only a few P. mirabilis isolates were reported resistant
in any year before 1999. Poisson regression showed strong
evidence of a trend to increasing resistance for all four organ-
isms and suggested that these increases had a nonlinear com-
ponent for E. coli, enterobacters, and klebsiellae. If the trends
nevertheless were approximated to be linear, the average
annual increases in the proportion of resistant isolates were as
follows: E. coli, 21.54% (95% confidence intervals [CI] 18.86-
24.30); Klebsiella spp., 6.97% (CI 4.41-9.59); Enterobacter
spp. 13.97% (CI 10.46-17.58); and P. mirabilis, 21.31% (CI
11.38-32.13).
Distribution of Resistance
To assess the distribution of resistance, we counted, for
each organism in each year: 1) the number of laboratories
reporting resistant isolates, 2) any laboratories contributing
>10% of all reports of resistance, and 3) the proportion of
reports of resistance from the top three contributors (Table 2).
The last two criteria were applied only when >30 resistant iso-
lates of a species were reported in a year, so that a hospital
would not appear as a “major contributor” on the basis of three
or fewer resistant isolates. 
The number of laboratories reporting resistant E. coli rose
from 25 in 1990 to 89 in 1999, and no single laboratory ever
contributed >10% of all reports of resistance in a year for this
species. Laboratories reporting five or more resistant E. coli in
years before 1998 mostly served major teaching hospitals, but
many district general hospitals reported five or more resistant
E. coli isolates in 1998 and 1999. Resistance was more local-
ized and more prevalent in Klebsiella and Enterobacter spp.
than in E. coli. The number of laboratories reporting resistant
klebsiellae fluctuated from 36 to 57 after 1992, without obvi-
ous trend. During a peak in resistance prevalence, from 1995
to 1997, one or two laboratories each contributed >10% of all
reports of resistant klebsiellae, and the top three contributors
accounted for 32% to 39% of reports of resistance. For Entero-
bacter spp., laboratories reporting resistance increased from
10 in 1990 to 36 in 1992, then fluctuated with little trend until
1997, before rising to 40 in 1998 and 58 in 1999. In the peak of
resistance in 1995 and 1996, two laboratories each accounted
for >10% of all reports of resistant enterobacters, and 30% to
32% of reports of resistance came from the top three contribu-
tors. Resistance was uncommon in P. mirabilis, and clusters
were not evident. 
In a further analysis, we identified eight laboratories that
frequently reported large numbers of resistant E. coli, Kleb-
siella spp., and Enterobacter spp. during the entire surveil-
lance period. These were in major metropolitan areas  and
served teaching hospitals. These laboratories accounted for
7.7%, 11.2%, and 10.3% of reports with ciprofloxacin data for
E. coli, Klebsiella, and Enterobacter spp. respectively, but for
18.2%, 30.9%, and 22.4%, respectively, of reports ofEmerging Infectious Diseases  •  Vol. 8, No. 5, May 2002 475
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resistance in these organisms, confirming a major excess of
resistance. 
The prevalence of ciprofloxacin resistance was examined in
relation to patients’ ages for E. coli, since those aged <14 years
should not receive fluoroquinolones. Taking the period 1995
through 1999 as a whole, 12 (3.9%) of 305 E. coli with data
from patients 1 to 14 years old were reported as ciprofloxacin
resistant, compared with 778 (3.2%) of 24,302 E. coli isolates
from patients aged >15 years. These data indicated a relative
risk of 1.22 (95% CI 0.7-2.1) for the younger patients. Similar
calculations were not performed for other species because of
the small numbers of source patients ages 1-14 years.
Use of Fluoroquinolones
Fluoroquinolone use increased in the earlier years of sur-
veillance, nearly doubling from 1990 to 1993. However, usage
has been relatively stable from 1997 onwards, with commu-
nity use declining slightly (Figure 2). Although most use is
still in the community, hospital use has grown steadily in abso-
lute terms and as a proportion, constituting 31.5% of total use
in 1999 compared with 18.9% in 1992. Ciprofloxacin was the
dominant fluoroquinolone throughout the period (not shown).
Conclusion
When this surveillance began in 1990, the ciprofloxacin
resistance rates in E. coli and P. mirabilis were <1%, and rates
for enterobacters and klebsiellae were 2.1% and 3.5%, respec-
tively. The prevalence of resistance in E. coli subsequently
rose slowly and progressively to reach 3.7% in 1999; this
resistance was widely scattered in hospitals. Resistance also
increased significantly (p<0.01, chi-square test for trend) in
enterobacters and klebsiellas. The prevalence rates for these
two genera were strongly influenced by clusters of resistant
isolates reported by a few laboratories. Thus, the prevalence of
ciprofloxacin resistance in klebsiellae peaked at 9.5% in 1996,
when three laboratories accounted for 35% of reports of resis-
tance. A subsequent decline was associated with the absence
of clusters but not with a decline in the number of hospitals
that reported resistance. For enterobacters, the proportion of
resistant isolates rose from 1990 to 1996, but the number of
laboratories reporting resistance was relatively constant from
1992 to 1997. Peak rates of resistance in 1995 and 1996 were
in a period when the top three contributors accounted for 30%
to 32% of reports. Resistance in P. mirabilis was infrequent
and scattered but rose significantly (p<0.01) in prevalence. 
Although our analysis of resistance prevalence depended
on the compilation of susceptibility results obtained at differ-
ent sites by different methodologic variants, there is no sug-
gestion that definitions of resistance to ciprofloxacin have
become more conservative in the United Kingdom. Moreover,
a rising prevalence of ciprofloxacin resistance is evident in the
smaller numbers of E. coli isolates tested by a standardized
method at the Central Public Health Laboratory, supporting the
trends found here (7,9).
Several factors may explain the greater prevalence and
clustering of resistance in enterobacters and klebsiellae. Most
Table 1. Ciprofloxacin-resistant Enterobacteriaceae reported from bacteremias, England and Wales, 1990–1999
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
Escherichia coli
   Total no. reports 7,610 7,377 7,849 7,872 8,274 8,465 9,155 10,143 11,248 11,573
   No. with cipro. results 4,171 4,456 5,036 5,071 5,136 5,143 4,559 3,706 6,282 6,708
   No. reported ciproR  33 32 47 65 88 108 119 144 244 246
Klebsiella spp.
   Total no. reports 1,544 1,634 1,710 1,725 1,791 1,957 2,143 2,383 2,816 2,802
   No. with cipro. results 821 1,082 1,124 1,141 1,173 1,256 1,137 900 1,551 1,578
   No. reported ciproR  29 48 55 77 77 115 108 80 125 112
Enterobacter spp.
   Total no. reports 895 912 1,013 948 1,118 1,089 1,229 1,480 1,638 1,629
   No. with cipro. results 582 636 743 759 815 723 617 534 908 949
   No. reported ciproR  12 26 36 29 54 65 65 55 72 103
Proteus mirabilis
   Total no. reports 868 898 911 925 984 942 1,244 1,131 1,241 1,145
   No. with cipro. results 454 578 560 573 635 673 578 447 715 658
   No. reported ciproR  2 3 1 7 14 7 4 5 14 22
   No. of other organisms 19,866 20,458 21,335 22,968 23,559 24,545 27,908 31,258 34,517 34,216
Total bacteremia reports 30,783 31,279 32,838 34,438 35,726 36,948 41,679 46,395 51,100 51,365
Cipro, ciprofloxacin; R, resistant.RESEARCH
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importantly,  Enterobacter and Klebsiella spp. are primarily
hospital pathogens, whereas E. coli bacteremias are more often
community acquired. Thus, E. coli accounted for 22.8% of all
bacteremias in this surveillance, which included both hospital-
and community-acquired infections, but only 12.5% of hospi-
tal-acquired bacteremias, as recorded by the Nosocomial
Infection National Surveillance Scheme (10). Although most
fluoroquinolone use is in the community (Figure 2), the most
intensive use and therefore the greatest selection pressure rela-
tive to numbers and concentration of patients is in hospitals.
Moreover  Klebsiella and Enterobacter infections are more
often clonal than those involving E. coli; single strains, per-
haps resistant, spread to numerous patients (11). Clonal out-
breaks seem the likely explanation when small numbers of
hospitals contributed substantially to resistance totals—as was
often the case for Enterobacter and Klebsiella spp. (Table 2)—
but cannot be proved without retained isolates. Bacteremias
caused by quinolone-resistant E. coli may or may not be
clonal, even when multiple cases occur in a unit (12,13). The
laboratories reporting clusters of resistant Enterobacter and
Figure 1.  Resistance trends in
Escherichia coli,  Klebsiella spp.,
Enterobacter spp., and Proteus
mirabilis, England and Wales,
1990–1999.*
*Bars indicate 95% confidence
intervals.
Table 2. Distribution of reports of ciprofloxacin resistance for Enterobacteriaceae from bacteremia in hospitals, England and Wales, 1990–1999
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
Escherichia coli
   No. labs reporting ciproR  isolates 25 29 39 40 57 52 58 68 94 89
    Labs contributing >10% of ciproR total (n)a 1000000000
   % of all ciproR reports from top three contributorsa 33 19 17 20 13 19 26 17 11 12
Klebsiella spp.
   No. labs reporting ciproR isolates 23 48 38 42 42 47 42 36 57 50
   Labs contributing >10% of ciproR total (n)a -010012210
   % of all ciproR reports from  top three contributorsa - 1 72 91 52 13 23 53 92 32 1
Enterobacter spp.
   No. labs reporting ciproR isolates 10 19 36 27 37 30 35 33 39 58
   Labs contributing >10% of ciproR total (n)a --0-022000
   % of all ciproR reports from top three contributorsa - - 2 8 - 2 23 23 02 22 21 6
Proteus mirabilis 
   N o .  l a b s  r e p o r t i n g  c i p r o R   i s o l a t e s 2216 1 2 636 1 2 2 0
   Labs contributing >10% of ciproR total (n) a ----------
    % of all ciproR reports from  top three contributorsa ----------
aNot calculated if <30 resistant isolates.
Cipro, ciprofloxacin; R, resistant; labs, laboratories.Emerging Infectious Diseases  •  Vol. 8, No. 5, May 2002 477
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Klebsiella spp. mostly served major teaching hospitals, where
fluoroquinolone prophylaxis by hematology departments has
been associated with a reduced incidence of bacteremias in
neutropenic patients (14) but with more bacteremias being
caused by fluoroquinolone-resistant strains (15,16).
We did not attempt to comprehensively relate resistance
and prescribing, but three general points can be made. First,
the recent decline in community prescribing of fluoroquino-
lones (Figure 2) has not affected the upward resistance trend in
E. coli, although most E. coli bacteremia is believed to involve
non-nosocomial strains. Second, the rising hospital use of flu-
oroquinolones has not been mirrored by an acceleration in
upward trend of resistance in Klebsiella and Enterobacter spp.
Third, the prevalence of resistant E. coli from bacteremias in
patients 1-14 years old was similar to or higher than that in
older patients, although the younger patients should not
receive fluoroquinolones. These observations imply complex
relationships between use and resistance, demanding prospec-
tive investigation.
Except for P. mirabilis, the resistance prevalence rates
found here resemble those for bacteremias in the United
States, a country with much heavier fluoroquinolone use than
the United Kingdom. The Surveillance Network database
(http://www.mrlworld.com) shows resistance trends (with
intermediate counted as resistant) in bloodstream isolates from
250 U.S. hospitals as follows: E. coli, 1.8% in 1996 and 4.3%
in 1999; Klebsiella spp., 7.1% in 1996 and 6.7% in 1999;
Enterobacter spp., 6.6% in 1996 and 6.5% in 1999; and P.
mirabilis, 5.7% in 1996 and 12.7% in 1999. Much higher rates
are reported from Barcelona, Spain, where 17% of E. coli iso-
lates from community infections were ciprofloxacin resistant
(17), and India, where up to 50% of hospital E. coli are
reported resistant (18). High rates in E. coli may reflect con-
tamination via the food chain: the Spanish study found qui-
nolone-resistant E. coli in 90% of chicken feces and noted
similar fecal carriage rates of resistant E. coli in children and
adults. Acquisition of resistant E. coli via the food chain may
also explain why, in our study, resistant E. coli were reported
from age groups who should not receive fluoroquinolone ther-
apy and its contingent selection pressure.
Ciprofloxacin remains a potent antibiotic; but the slow
accumulation of resistant Enterobacteriaceae is disturbing, not
least because resistance is a class effect, affecting all fluoro-
quinolones. Ultimately, this resistance may be partly overcome
by inhibiting the efflux pumps that contribute to the resistance
(19), but this strategy is still several years from fruition. In the
interim, the best approach lies in the prudent use of fluoroqui-
nolones in humans and animals, coupled with an emphasis on
preventing patient-to-patient spread of resistant strains. 
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